Adhera Therapeutics Probability of Future Pink Sheet Price Finishing Under 0.61
| ATRXDelisted Stock | USD 0.72 0.00 0.00% |
Adhera |
Adhera Therapeutics Target Price Odds to finish below 0.61
The tendency of Adhera Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 0.61 or more in 90 days |
| 0.72 | 90 days | 0.61 | about 15.8 |
Based on a normal probability distribution, the odds of Adhera Therapeutics to drop to $ 0.61 or more in 90 days from now is about 15.8 (This Adhera Therapeutics probability density function shows the probability of Adhera Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Adhera Therapeutics price to stay between $ 0.61 and its current price of $0.72 at the end of the 90-day period is about 30.81 .
Given the investment horizon of 90 days Adhera Therapeutics has a beta of 0.83. This suggests as returns on the market go up, Adhera Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Adhera Therapeutics will be expected to be much smaller as well. Additionally Adhera Therapeutics has an alpha of 0.1841, implying that it can generate a 0.18 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Adhera Therapeutics Price Density |
| Price |
Predictive Modules for Adhera Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Adhera Therapeutics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Adhera Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Adhera Therapeutics is not an exception. The market had few large corrections towards the Adhera Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Adhera Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Adhera Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.18 | |
β | Beta against Dow Jones | 0.83 | |
σ | Overall volatility | 0.12 | |
Ir | Information ratio | 0.01 |
Adhera Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Adhera Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Adhera Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Adhera Therapeutics is not yet fully synchronised with the market data | |
| Adhera Therapeutics has some characteristics of a very speculative penny stock | |
| Adhera Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Adhera Therapeutics currently holds 7.35 M in liabilities with Debt to Equity (D/E) ratio of 56.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Adhera Therapeutics has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Adhera Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Adhera Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Adhera Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Adhera to invest in growth at high rates of return. When we think about Adhera Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (6.35 M) with loss before overhead, payroll, taxes, and interest of (157 K). | |
| Adhera Therapeutics currently holds about 849 K in cash with (665 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 22.0% of Adhera Therapeutics shares are held by company insiders |
Adhera Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Adhera Pink Sheet often depends not only on the future outlook of the current and potential Adhera Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Adhera Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 17 M | |
| Short Long Term Debt | 6.7 M | |
| Shares Float | 2.3 M |
Adhera Therapeutics Technical Analysis
Adhera Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Adhera Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Adhera Therapeutics. In general, you should focus on analyzing Adhera Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Adhera Therapeutics Predictive Forecast Models
Adhera Therapeutics' time-series forecasting models is one of many Adhera Therapeutics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Adhera Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Adhera Therapeutics
Checking the ongoing alerts about Adhera Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Adhera Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Adhera Therapeutics is not yet fully synchronised with the market data | |
| Adhera Therapeutics has some characteristics of a very speculative penny stock | |
| Adhera Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Adhera Therapeutics currently holds 7.35 M in liabilities with Debt to Equity (D/E) ratio of 56.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Adhera Therapeutics has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Adhera Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Adhera Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Adhera Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Adhera to invest in growth at high rates of return. When we think about Adhera Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (6.35 M) with loss before overhead, payroll, taxes, and interest of (157 K). | |
| Adhera Therapeutics currently holds about 849 K in cash with (665 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 22.0% of Adhera Therapeutics shares are held by company insiders |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Adhera Pink Sheet
If you are still planning to invest in Adhera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Adhera Therapeutics' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |